Lipoprotein(a) is an independent risk factor for multiple cerebral infarctions

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 29-32

  Hiraga, Takaki ^a   Shimada, Masako ^a   Okubo, Minoru ^a   Nakanishi, Kohji ^a   Kobayashi, Tetsuro ^a   Murase, Toshio ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hypertension; Lipoprotein(a); Multiple cerebral infarctions; Non insulin dependent diabetes mellitus

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029925807     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05743-9     Document Type: Article

References (23)

1. Utermann G. The mysteries of lipoprotein (a). Science 1989;246:904.
2. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709.
3. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963;59(suppl):166.
4. Liu AC, Lawn RM. Vascular interactions of lipoprotein (a). Curr Opin Lipidol 1994;5:269.
5. Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T. Prospective study of lipoprotein (a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes mellitus. Diabetes Care 1995;18:241.
6. Yamazaki T, Katoh K, Nakanishi S, Nishiyama S, Seki A, Okubo M, Murase T. Lp(a) predicts the severity of coronary artery disease. Coron Artery Dis 1992;3:57.
7. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199.
8. Kawakami K, Tsukada A, Okubo M, Tsukada T, Kobayashi T, Yamada N, Murase T. A rapid electrophoretic method for the detection of serum Lp(a) lipoprotein. Clin Chim Acta 1989;185:147.
9. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942.
10. Woo J, Lau E, Lam CWK, Kay R, Teoh R, Wong HY, Prall WY, Kreel L, Nicholls MG. Hypertension, lipoprotein(a), and apolipoprotein A-1 as risk factors for stroke in the Chinese. Stroke 1991;22:203.
11. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993;24:965.
12. Mohr JP. Lacunes. In: Barnett HJM, Stein BM, Mohr JP and Yatsu FM. (eds). Stroke Pathophysiology, Diagnosis, and Management, New York: Churchill Livingstone, Vol 2, 1986:475.
13. Alex M, Baron EK, Goldenberg S, Blumenthal HT. An autopsy of cerebrovascular accident in diabetes mellitus. Circulation 1962;25:6663.
14. Aronson SM. Intracranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol 1973;23:183.
15. Hiraga T, Okubo M, Kobayashi T, Nakanishi K, Sugimoto T, Murase T. Serum lipoprotein(a) levels differ in different phenotypes of primary hyperlipoproteinemia. Metabolism 1993;42:1327.
16. Bell D. Stroke in the diabetic patient. Diabetes Care 1994;17:213.
17. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. Atherosclerosis 1982;44:61.
18. Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 1988;66:462.
19. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JI. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313.
20. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271.
21. Adult Treatment Panel II. National Cholesterol Education Program: Second report of the Expert Panel on detection, valuation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1333.
22. Hiraga T, Harada K, Kobayashi T, Murase T. Reduction of serum lipoprotein(a) using estrogen in a man with familial hypercholesterolemia. J Am Med Assoc 1992;267:2328.
23. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989;339:301.